HCV / Hepatitis

The gene USP26 is identified as a factor in hepatocellular carcinoma development and a potential therapeutic target.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.

The results indicate that paternal hepatitis B virus infection before pregnancy is linked to a 40% higher risk of congenital heart diseases in their children.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

With the ongoing war between Israel and Hamas, The World Health Organization reported a public health update. Officials are concerned about what is happening inside the Gaza Strip particularly around a variety of diseases and health conditions including hepatitis A, skin infections, and even polio.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Findings affirm the safety and efficacy of using HBsAg-positive donor kidneys in HBsAg-negative recipients, with no adverse effects on posttransplant outcomes.

Recent analysis suggests that stricter COVID-19 measures could have saved thousands, Danjuma Adda calls for more funding and awareness to tackle viral hepatitis, our second episode of From Pathogen to Infectious Disease podcast, and more this week.

Increased funding can lead to the development of resources like rapid diagnostic test kits and improve the overall availability of treatment for those in need.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

This upcoming Sunday, July 28, is this year’s World Hepatitis Day and it is an opportunity to raise awareness, deliver education to the masses, and continue to support the research and treatments to reduce the incidence rates of the infection.

The OraQuick HCV self-test aims to improve testing access and help individuals detect the disease affecting an estimated 58 million people worldwide.

An outside physician who was working at 3 hospitals in the Portland, Oregon area did not follow infection prevention protocols, leaving patients potentially exposed to bloodborne infections.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

Monitoring viral genetic changes in patients during ribavirin therapy could help identify those at risk for Hepatitis E Virus treatment failure.

Data gaps prompt the development of enhanced models revealing stagnant HCV rates, worsened by increasing injection drug use, requiring expanded testing and targeted interventions for underserved populations.

The liver’s under appreciated hepatocytes play a role in helping in to keep the body healthy, so be good to it so you won’t contract liver-related diseases such as hepatitis or other conditions.

The healthcare sector currently faces an unmet need in treating herpesviruses, hepatitis B, and hepatitis D, which could significantly improve patient outcomes. Addressing this involves considering the necessary steps and understanding the challenges pharmaceutical companies encounter as they work towards developing treatments for these conditions.

Colorado man infected with avian influenza, Novavax reveals promising results in JN1 covid vaccine efficacy, and recent roundups of c difficile news, and more from Contagion.

The test was validated as part of the NIH’s RADx tech program through its Independent Test Assessment Program, in collaboration with the FDA.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.